Hospira Receives FDA Approval for Six New Presentations of Heparin
31 Agosto 2009 - 5:45PM
PR Newswire (US)
-- Heparin Product Offering Now Among Broadest Available -- LAKE
FOREST, Ill., Aug. 31 /PRNewswire-FirstCall/ -- Hospira, Inc.
(NYSE: HSP), the world leader in generic injectable
pharmaceuticals, today announced that the U.S. Food and Drug
Administration (FDA) has approved the company's applications for
six new presentations of therapeutic heparin in single- and
multiple-dose vials. Heparin is used to prevent clot formation in
central venous catheters and for anticoagulant (blood thinning)
therapy, and is available in numerous delivery systems for
different modes of administration. The six new vial presentations
of heparin approved by the FDA range in volume from one milliliter
to 30 milliliters, and in concentration from 1,000 units per
milliliter to 10,000 units per milliliter. Hospira recognizes the
clinical need for this important medication and sought to expand
its marketed portfolio of heparin presentations to help meet market
demand. With the addition of the new vials, Hospira now offers one
of the broadest portfolios of heparin available on the U.S. market,
with various sizes and strengths of the product available in
syringes, vials and flexible containers. "Hospira is committed to
ensuring patient access to safe and effective supplies of heparin,"
said Joshua Gordon, vice president, Specialty Pharmaceuticals,
Hospira. "These additional presentations will provide our customers
a wide range of options to address the continuum of care." About
Hospira Hospira, Inc. is a global specialty pharmaceutical and
medication delivery company dedicated to Advancing Wellness(TM). As
the world leader in specialty generic injectable pharmaceuticals,
Hospira offers one of the broadest portfolios of generic acute-care
and oncology injectables, as well as integrated infusion therapy
and medication management solutions. Through its products, Hospira
helps improve the safety, cost and productivity of patient care.
The company is headquartered in Lake Forest, Ill., and has
approximately 14,000 employees. Learn more at
http://www.hospira.com/.
http://www.newscom.com/cgi-bin/prnh/20040503/HSPLOGO
http://photoarchive.ap.org/ DATASOURCE: Hospira, Inc. CONTACT:
Media, Dan Rosenberg, +1-224-212-3366, or Financial Community,
Karen King, +1-224-212-2711, both of Hospira, Inc. Web Site:
http://www.hospira.com/
Copyright